| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 06 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
I am pleased to nominate you as a member of the board of directors (the “Board”) of Fractyl Health, Inc., a Delaware corporation (the “Company”). |
| 22 Oct 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance |
| 16 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
October 2026 REMAIN-1 Pivotal Study Positive Topline 6 Month Results for Revita in Post-GLP-1 Weight Maintenance Revita is for investigational use only in the United States. Revita has a CE mark in the EU/UK. REMAIN-1 is an ongoing study... |
| 01 Oct 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Fractyl Health, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), certifies: |
| 24 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 24, 2026, Fractyl Health, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). Of the 159,179,848, shares of the Company’s common stock outstanding as of the record date of August 21, 2026, ... |
| 11 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on March 13, 2026, Fractyl Health, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common ... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-f... |
| 15 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
Positive One-Year Randomized REMAIN-1 Midpoint Cohort Results July 15, 2026 Revita is for investigational use only in the United States. Revita has a CE mark in the EU/UK. Exhibit 99.2 |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2026, Fractyl Health, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 158,648,963 shares of the Company’s common stock outstanding as of the record date of April 17, 2026, 112,... |
| 04 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Next anticipated Revita® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 |
| 11 May 2026 |
8-K: Regulation FD Disclosure
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes |
| 24 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 |
| 17 Mar 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On March 13, 2026, Fractyl Health, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in complian... |
| 26 Feb 2026 |
8-K: Regulation FD Disclosure
Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 |
| 29 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita®After GLP-1 Discontinuation |
| 06 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Employment Agreement (this “Agreement”), dated as of December 30, 2025, is made by and between Fractyl Health, Inc. a Delaware corporation (together with any successor thereto, the “Company”), and Lara Smith Weber (“Executive”) (col... |
| 05 Jan 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 |
| 16 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Fractyl Health, Inc. (the “Company”) hereby gives notice that it is calling for cancellation, at 6:30 p.m., New York City time, on December 30, 2025 (the “Cancellation Date”), all of the Company’s outstanding Tranche A Common Stock Purch... |
Loading...